

**Title:** Accuracy and reliability of self-administered visual acuity tests: Systematic review of pragmatic trials

**Short Title:** Accuracy and reliability of self-administered visual acuity tests

**Authors:** Arun James Thirunavukarasu<sup>1,2,\*</sup>, Refaat Hassan<sup>1,3</sup>, Aaron Limonard<sup>1,4</sup>, Shalom Vitreous Savant<sup>1,4</sup>

**Affiliations:** <sup>1</sup>University of Cambridge School of Clinical Medicine, Cambridge, UK; <sup>2</sup>Corpus Christi College, University of Cambridge, Cambridge, UK; <sup>3</sup>Sidney Sussex College, University of Cambridge, Cambridge, UK; <sup>4</sup>St John's College, University of Cambridge, Cambridge, UK

**\*Corresponding author:** Arun Thirunavukarasu, Corpus Christi College, Cambridge, CB2 1RH, UK; [ajt205@cantab.ac.uk](mailto:ajt205@cantab.ac.uk)

**Author contributions:** AJT conceived and led the study. AJT prepared the study protocol and implemented the search strategy. AL, SVS, and AJT undertook abstract screening; AJT and RH undertook full-text screening, quality assessment, and data extraction. AJT conducted data analysis and produced figures. AJT drafted the manuscript with feedback from AL, SVS, and RH. All authors approved the final draft for submission.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Abstract

### *Background:*

Remote self-administered visual acuity (VA) tests have the potential to allow patients and non-specialists to assess vision without eye health professional input. Validation in pragmatic trials is necessary to demonstrate the accuracy and reliability of tests in relevant settings to justify deployment.

### *Methods:*

A systematic review was undertaken in accordance with a preregistered protocol (CRD42022385045). The Cochrane Library, Embase, MEDLINE, and Scopus were searched. Screening was conducted according to the following criteria: (1) English language; (2) primary research article; (3) visual acuity test conducted remotely; (4) no clinical administration of remote test; (5) accuracy or reliability of remote test analysed. There were no restrictions on trial participants. Quality assessment was conducted with QUADAS-2.

### *Results:*

Of 1227 identified reports, 10 studies were ultimately included. One study was at high risk of bias and two studies exhibited concerning features of bias; all studies were applicable. Three trials—of DigiVis, iSight Professional, and Peek Acuity—from two studies suggested that accuracy of the remote tests was comparable to clinical assessment. All other trials exhibited inferior accuracy, including conflicting results from a pooled study of iSight Professional and Peek Acuity. Two studies evaluated test-retest agreement—one trial provided evidence that DigiVis is as reliable as clinical assessment. The three most accurate tests required access to digital

devices. Reporting was inconsistent and often incomplete, particularly with regards to describing methods and conducting statistical analysis.

*Conclusions:*

Remote self-administered VA tests appear promising, but further pragmatic trials are indicated to justify deployment at scale to facilitate patient or non-specialist led assessment which could augment teleophthalmology, non-specialist eye assessment, pre-consultation triage, and autonomous long-term monitoring of vision.

## Introduction

Visual acuity (VA) is a measure of the functional resolution of vision, and is assessed before every ophthalmological, optometric, and orthoptic examination to inform decision making. Generally, VA assessment involves a clinician appraising the smallest optotype the patient can read while at a standard distance away from an illuminated chart. Self-administered VA tests provide patients with a means of monitoring their vision without having to be examined by an eye health professional. These tests may augment telehealth services, as VA assessment is an integral part of any eye examination. Adoption of self-administered VA tests may reduce the burden on strained ophthalmology resources by enabling non-specialists to triage with knowledge of visual function; by improving referral quality with provision of VA data; and by facilitating autonomous monitoring of vision by patients with chronic eye conditions (who otherwise require frequent clinic appointments).<sup>1-3</sup> Many remote visual acuity tests have been developed, but most require administration in real time by a trained clinician, as required with conventional VA assessment (such as with Snellen or ETDRS chart).<sup>4-6</sup>

As the requirement for clinical examination limits the usefulness of ophthalmic telehealth services, platforms facilitating further examination without physical attendance will serve as important components of any improved suite for remote consultation.<sup>3,6</sup> Many remote clinician-administered tests have been developed and applied in a wide variety of clinical settings around the world.<sup>1,4</sup> However, removing the requirement for clinical administration is essential for remote VA tests to empower non-specialists and patients to test their vision. In recent years, newer platforms have emerged with this capability,<sup>7</sup> and impetus for validation and

implementation has been provided by the COVID pandemic.<sup>1,8,9</sup> Most validation studies either involve clinical administration or are conducted in optimised clinical environments, unrepresentative of remote self-testing by patients at home or away from the eye unit.<sup>4</sup> Pragmatic trials are essential to demonstrate that remote tests are useful for generating actionable VA data without skilled supervision—artificial environments are expected to inflate accuracy and reliability.<sup>10,11</sup> Validation data generated in unrealistic settings provides weaker justification for subsequent clinical deployment than results generated in real-world conditions.<sup>11</sup>

Here, a systematic review was undertaken to identify remote self-administered VA tests; appraise the quality of their validation data; and compare these tests to conventional visual acuity testing. Specifically, the accuracy and reliability of VA self-tests were gauged, to establish the clinical utility of available platforms. All trials were pragmatic in that remote tests were administered without real-time clinical input, away from artificially ideal conditions. This evidence synthesis serves as a point of reference for clinicians, patients, and policy makers interested in identifying appropriate platforms to facilitate visual acuity assessment without requiring eye health service involvement.

## **Materials and Methods**

This systematic review adhered to PRISMA guidance, according to a prospectively registered protocol on PROPERO (identifier CRD42022385045). On 23 December 2022, The Cochrane Library, Embase (via OVID), MEDLINE (via PubMed), and Scopus were searched for the following: ("visual acuity") AND ("remot\*" OR "portable" OR "home based") AND ("test" OR "assessment" OR "examination").

Previously published reviews were also searched for relevant studies.<sup>4-7</sup> Duplicates were removed by a single researcher using Zotero (version 6.0.19-beta.15+6374aea1c; Digital Scholar, Vienna, Virginia, USA). Abstract and full text screening were undertaken by two independent researchers in Rayyan,<sup>12</sup> with a third researcher acting as arbiter to resolve disagreement. The following inclusion criteria were employed: (1) Written in the English language; (2) Is a peer-reviewed primary research article; (3) Study examines a visual acuity test undertaken out of clinic (*i.e.* remotely); (4) The remote test does not require a clinically trained administrator (*i.e.* patient-led); (5) The remote patient-led test is compared to clinical or repeated remote visual acuity measurements to assess accuracy or reliability, respectively. No restrictions were placed on participant characteristics or test modality.

Risk of bias and concerns regarding applicability were appraised with the QUADAS-2 framework by a single researcher, with a second researcher verifying each appraisal.<sup>13</sup> One researcher undertook data extraction for each included study, with a second independent researcher verifying every entry. Data gathered included details about participants, index tests, reference tests, measured outcomes, and study designs; and for index test-retest reliability and accuracy (*i.e.* comparison to clinical reference test), the bias and limits of agreement of Bland-Altman plots, correlation coefficients and  $p$  value, and  $t$ -test  $p$  value. For consistency, bias was expressed as the mean difference between reference and index test, such that positive values indicated that the reference test tended to provide a higher value (*i.e.* where the index test overestimated visual acuity). Where studies provided individual participants' VA data without further analysis, the two-way random effects

intraclass correlation coefficient (ICC) was calculated, and unpaired two-samples  $t$ -test was conducted. For studies exhibiting Bland-Altman plots without reporting figures for the bias and limits of agreement, manual interpolation was conducted with WebPlotDigitizer (version 4.6.0; Ankit Rohatgi, Pacifica, California, USA; company). Meta-analysis was planned but ultimately precluded by a lack of trials testing the same platform. Data extraction and quality assessment were conducted in Microsoft Excel for Mac (version 16.57; Microsoft Corporation, Redmond, Washington, USA). Data analysis was conducted in R (version 4.1.2; R Foundation for Statistical Computing, Vienna, Austria).<sup>14–16</sup> Tables were produced in Microsoft Excel for Mac. Figures were produced in R and modified with Affinity Designer (version 1.10.4; Pantone LLC, Carlstadt, New Jersey, USA).

## Results

The undertaken literature search and screening process is summarised in Figure 1. 10 studies were included from 1227 identified reports.<sup>17–26</sup> Fulfilling criterion (3) necessitated that trials were pragmatic in that remote tests were conducted out of the eye clinic.<sup>27</sup> Hyperacuity tests and survey-based self-assessment were excluded.<sup>28–31</sup> To fulfil criterion (4), tests had to be patient-led: while tests administered by parents for paediatric patients were acceptable, involvement of clinicians or other trained personnel justified exclusion.<sup>32–34</sup> Criterion 5 mandated exclusion of studies involving tests which did not provide visual acuity measurements which could be compared to conventional clinical assessment or repeated remote measurement.<sup>35–37</sup>

**Figure 1. PRISMA flowchart.** Illustrating the literature search, screening process, and articles included in this review. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta Analyses; MEDLINE = Medical Literature Analysis and Retrieval System Online.

Study characteristics are summarised in Table 1. Most studies were prospective cross-sectional surveys, with just one retrospective case-control study. 6 of 10 studies reported conflicts of interest, suggesting that many validation studies were not undertaken by research teams independent from the trialled product—a potential source of reporting bias. However, none of the included studies received private funding, such as from product manufacturers. The number of participants ranged from 7 to 148 (median = 50.5). Reported participant age ranged from 3 to 95 years old—spanning most of the paediatric and adult ophthalmology case load. Most trialled tests required access to digital devices: exceptions required a paper chart or custom-built e-device; both provided by the investigators.<sup>19,26</sup> One study required patients to print a physical chart sent to their digital device.<sup>24</sup> Risk of bias judged with QUADAS-2 was generally low, as illustrated in Figure 2 and S1 Figure. No major concerns regarding applicability were highlighted during QUADAS-2 appraisal, likely due to stringent inclusion criteria ensuring all studies applied patient-led tests remotely.

**Figure 2. Risk of bias and inapplicability appraisals for each included study.**

Appraised with the QUADAS-2 framework. QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies 2; RoB = risk of bias; CrA = concerns regarding applicability.



Citation	Funding	Conflict of interest	Country of corresponding author	Participants	Index test	Index test hardware	Reference test	Outcome	Study design
Adyanthaya and B, 2022	None	None	India	N=148; 6-14 years old; all had non-acute ocular symptoms	(1) iSight Professional (2) Peek Acuity	Apple and Android smartphones	Snellen chart at 6m in clinic	Distance BCVA in logMAR	Cross-sectional survey
Almagati and Kran, 2021	Public	Previous co-authorship between reviewer and co-author	United States of America	N=7; 3-7 years old; low vision clinic patients: 3 with cerebral visual impairment, 4 without	FrACT Landolt-C (1) University of Arizona/Banner Eye Health Chart (2) Verana Vision Test (3) Farsight.care	Digital internet connected devices	Most recent clinical assessment	Distance BCVA in logMAR	Case control
Bellsmith et al, 2022	Public	None	United States of America	N=121; 18-78 years old; eye clinic patients with VA of 20/200 Snellen or better		Apple device, internet-connected computer, or paper chart	Electronic Snellen chart in clinic	Distance BCVA in logMAR	Cross-sectional survey
Chen et al, 2022	None	Co-authors invented and hold patent for the trialled test; co-author consults for KYS Vision Co-author paid by Zeiss, Allergan, Vanda, and Long Bridge Medical	United States of America	N=25; all over 18 years old; retina clinic patients with VA of 20/200 Snellen or better	Acustat	Digital internet connected devices	Snellen chart in clinic	Near BCVA in logMAR	Cross-sectional survey
Chen et al, 2021	Public	None	United States of America	N=45; glaucoma clinic patients with VA better than 20/125 N=15; paediatric ophthalmology patients with a previously recorded VA	Letter Distance Chart PDF document	Digital device	Electronic Snellen chart in clinic	Distance BCVA in logMAR	Cross-sectional survey
Painter et al, 2021	Not stated	None	United Kingdom	N=27; emergency department patients with an ophthalmology consult ordered N=108; 18-85 years old; patients with ophthalmology appointment scheduled with	(1) iSight Professional (2) Peek Acuity	Smartphone or tablet	Most recent clinical assessment (1) Rosenbaum near card (2) Snellen chart at 20 feet in ED	Distance BCVA in logMAR	Cross-sectional survey
Pathipati et al, 2016	None	None	United States of America	N=27; emergency department patients with an ophthalmology consult ordered N=108; 18-85 years old; patients with ophthalmology appointment scheduled with	Paxos Checkup	Fourth generation Apple iPod Touch	ETDRS chart at 4m in clinic	Distance BCVA in ETDRS letters	Cross-sectional survey
Siktberg et al, 2021	Public	Co-author paid by Alcon Co-author invented and applied for patent for the trialled test; co-author is founding director of Cambridge Medical	United States of America	no prior recorded VA worse than 20/200	ETDRS vision chart PDF document	Internet-connected device and a printer	ETDRS chart at 4m in clinic	Distance BCVA in ETDRS letters	Cross-sectional survey
Thirunavukarasu et al, 2022	Public	Co-author consults for DORC International, Dutch Ophthalmic USA, and SurgiCube International; patent for trialled test pending	United Kingdom	N=120; 5-87 years old; patients with ophthalmology appointment scheduled with VA better than 0.8 logMAR	DigiVis	Digital internet connected devices	Clinical assessment in clinic	Distance BCVA in logMAR	Cross-sectional survey
Van Der Star et al, 2022	None	None	United States of America	N=56; 16-95 years old; patients with previous intraocular surgery or chronic ocular disease	Custom-built e-device	Custom built e-device with miniaturised Snellen chart virtually projected at 20 ft	Snellen chart at 20 feet in clinic	Distance BCVA in Snellen fraction	Cross-sectional survey

**Table 1. Characteristics of each of the included studies. BCVA = best corrected visual acuity; VA = visual acuity; logMAR = logarithm of the minimum angle of resolution; PDF = portable document format; ETDRS = Early Treatment of Diabetic Retinopathy Study.**

All studies gauged accuracy by comparing remote measurements to assessment in clinic (Table 2). The reference test was not consistently defined in three studies,<sup>18,22,25</sup> and Snellen chart was used in four studies;<sup>19–21,23,26</sup> as opposed to the gold-standard Early Treatment for Diabetic Retinopathy Study (ETDRS) chart which was used consistently in just one study.<sup>24</sup> One study trialling FrACT provided individualised data which enabled calculation of the bias and intraclass correlation coefficient, but its small sample size and retrospective design were discussed by the authors as significant limitations necessitating further validation.<sup>18</sup> One trial of a custom e-device did not report any statistical analysis or individual data.<sup>26</sup>

Citation	Index test	Reference test	N	Bias (95% CI)	LLOA (95% CI)	ULOA (95% CI)	Correlation (95% CI)	Correlation coefficient	Correlation coefficient <i>p</i> value	<i>t</i> -test <i>p</i> value
Adyanthaya and B, 2022	iSight Professional	Snellen chart	286 eyes of 148 patients	0.06 (0.04 to 0.08)	0.04	0.1				
Adyanthaya and B, 2022	Peek Acuity	Snellen chart	286 eyes of 148 patients	0.07 (0.05 to 0.09)	0.04	0.1				
Almagati and Kran, 2021	FrACT	Clinic assessment	14 eyes (binocular assessment) of 7 patients	-0.09			0.365 (-0.528 to 0.856)	ICC	0.195	0.63
Bellsmith et al, 2022	University of Arizona/Banner Eye Health Chart	Snellen chart	137 eyes of <121 patients	-0.07 (-0.1 to -0.04)	-0.39 (-0.44 to -0.34)	0.25 (0.20 to 0.30)	0.72 (0.62 to 0.79)	Pearson		
Bellsmith et al, 2022	Verana Vision Test	Snellen chart	147 eyes of <121 patients	-0.12 (-0.15 to -0.09)	-0.50 (-0.55 to -0.44)	0.26 (0.21 to 0.32)	0.58 (0.46 to 0.69)	Pearson		
Bellsmith et al, 2022	Farsight.care	Snellen chart	146 eyes of <121 patients	-0.13 (-0.16 to -0.10)	-0.53 (-0.58 to -0.46)	0.27 (0.21 to 0.33)	0.64 (0.53 to 0.73)	Pearson		
Chen et al, 2022	Acustat	Snellen chart	50 eyes of 25 patients		-0.2278	0.2235				0.8997
Chen et al, 2021	Letter Distance Chart PDF document	Snellen chart	45 eyes of 45 patients	-0.02	-0.31	0.26				0.28
Chen et al, 2021	Letter Distance Chart PDF document	Snellen chart	42 eyes of 42 patients	-0.02	-0.31	0.27				0.32
Painter et al, 2021	Professional or Peek Acuity	Clinic assessment	30 eyes of 15 patients	-0.14	-0.88	0.6				
Pathipati et al, 2016	Paxos Checkup	Rosenbaum near card	51 eyes from 27 patients	-0.06						0.264
Siktberg et al, 2021	ETDRS vision chart PDF document	ETDRS chart	209 eyes from 108 patients	0.078						
Thirunavukarasu et al, 2022	DigiVis	Clinic assessment	120 eyes from 120 patients	-0.001 (-0.017 to 0.015)	-0.175 (-0.202 to -0.147)	0.173 (0.146 to 0.201)	0.818 (0.748 to 0.869)	ICC	<0.001	
Van Der Star et al, 2022	Custom-built e-device	Snellen chart	72 eyes from 56 patients							

**Table 2. Accuracy data.** Comparing remote index tests to clinical reference tests. CI = confidence interval; LLOA = lower 95% limit of agreement; ULOA = upper 95% limit of agreement; ICC = intraclass correlation coefficient; PDF = portable document format; ETDRS = Early Treatment of Diabetic Retinopathy Study.

Eight studies provided Bland-Altman statistics, corresponding to trials of twelve remote VA tests (Figure 3).<sup>17,19–25</sup> Of these, six studies (ten trials) provided 95% lower and upper limits of agreement (LLOA and ULOA respectively).<sup>17,19–22,25</sup> Three trials' LOA lay within  $\pm 0.2$  logMAR, corresponding to Isight pro, Peek Acuity, and DigiVis.<sup>17,25</sup> The remaining seven trials corresponded to University of Arizona/Banner Eye Health Chart, Verna Vision Test, Farsight.care, Acustat, Letter Distance Chart PDF document (twice), and Isight pro or Peek Acuity pooled.<sup>19–22</sup> One study did not report the bias; of the remaining nine studies, three (containing six trials) provided 95% confidence intervals.<sup>17,19,25</sup> Isight pro and Peek Acuity exhibited significantly higher bias than 0 logMAR (index test estimated worse acuity);<sup>17</sup> University of Arizona/Banner Eye Health Chart, Verana Vision Test, and Farsight.care exhibited significantly lower bias than 0 logMAR (index test estimated better acuity);<sup>19</sup> and DigiVis exhibited no statistically significant bias.<sup>25</sup> The mean magnitude of the bias was 0.04 logMAR (2 letters).<sup>17–19,21–25</sup> Three studies (5 trials) reported (or facilitated calculation of) correlations: Pearson coefficients ranging from 0.58 to 0.72,<sup>19</sup> and two ICCs ranging from 0.365 to 0.818.<sup>18,25</sup> Four studies' (five trials) *t*-tests comparing measurement methods all reported *p*-values above 0.25.<sup>18,20,21,23</sup>

**Figure 3. Forest plot summarising Bland-Altman analyses of accuracy.** LLOA = lower 95% limit of agreement; ULOA = upper 95% limit of agreement; PDF = portable document format; ETDRS = Early Treatment of Diabetic Retinopathy Study; logMAR = logarithm of the minimum angle of resolution.

Two trials reported test-retest reliability: one trialling DigiVis,<sup>25</sup> and one trialling Isight pro and Peek Acuity in a pooled analysis.<sup>22</sup> The former reported Bland-Altman

statistics and intraclass correlation coefficient, whereas the latter only reported the coefficient of repeatability (Table 3). DigiVis exhibited a bias equivalent to 0, LOA of  $\pm 0.12$  logMAR (6 letters), and ICC of 0.922.<sup>25</sup> In a pooled analysis, Isight pro and Peek Acuity exhibited a coefficient of repeatability of 0.03 logMAR.<sup>22</sup>

Citation	Test	N	Bias (95% CI)	LLOA (95% CI)	ULOA (95% CI)	CoR (95% CI)	Correlation (95% CI)	Correlation Coefficient	Correlation coefficient p value
Painter et al, 2021	iSight Professional or Peek Acuity	26 eyes of 13 patients				0.03 (-0.08 to 0.04)			
Thirunavukarasu et al, 2022	DigiVis	105 eyes from 105 patients	0.001 (-0.011 to 0.013)	-0.121 (-0.142 to -0.101)	0.124 (0.103 to 0.144)		0.922 (0.887 to 0.946)	ICC	<0.001

**Table 3. Test-retest agreement.** Assessing the reliability of remote tests. CI = confidence interval; LLOA = lower 95% limit of agreement; ULOA = upper 95% limit of agreement; CoR = coefficient of repeatability; ICC = intraclass correlation coefficient.

## Discussion

To justify adoption of remote self-administered VA tests, there must be convincing evidence that the proposed platform meets regulatory safety standards, is effective enough to fulfil its clinical function, is accessible to patients—with appropriate mechanisms to serve those unable to use the platform, and is economically viable.<sup>38</sup> Facilities for VA self-assessment may be useful in a number of domains: improving the capacity and capability of teleophthalmology clinics, empowering patients with the ability to monitor their own vision rather than attend regular appointments; enabling non-eye specialists to obtain useful information for a referral to ophthalmology; and giving eye units a tool to facilitate pre-attendance triage of eye casualty cases.<sup>2,3</sup> In all cases, it is essential that tests are accurate and reliable, exhibiting agreement with clinical assessment and with repeated remote measurement, respectively.

In ideal conditions, chart-based VA still exhibits considerable variation, with 95% LOA approaching 0.09 logMAR.<sup>10</sup> In reality, clinical variation is greater as different examinations may be more or less demanding of patient effort, and may or may not test to majority failure (*i.e.*  $\geq 3$  errors on 1 line).<sup>39</sup> Where both index and reference test exhibit variation, the utility of analyses restricted to *t*-tests or correlation coefficients is limited. Bland-Altman analysis compensates for bivariate variation by quantifying 95% LOA, which provides metrics of measurement dispersal which can be compared to gold-standard tests. Studies failing to conduct appropriate analyses fail to provide evidence of validation—it is not possible to ascertain whether observed variation is clinically acceptable or not. Acceptable 95% LOA should compare well with those exhibited by conventional clinical chart-based tests: below  $\pm 0.2$  logMAR.<sup>39</sup> Bias should be close to zero—statistically significant deviation (*e.g.* if confidence intervals do not cross zero) indicates a systematic error. High correlation is expected—over 0.7 in terms of Pearson’s or intraclass correlation coefficients.<sup>40,41</sup>

Here, DigiVis was the only test exhibiting undisputed 95% LOA within 0.2 logMAR, no significant bias, and high correlation between remotely and clinically assessed VA.<sup>25</sup> iSight Professional and Peek Acuity exhibited 95% LOA within 0.2 logMAR in one of two studies, but this study was judged to be at a high risk of bias.<sup>17</sup> In the trial finding greater LOA, pooling of results from both tests may have affected calculated accuracy.<sup>22</sup> Just two studies reported test-retest agreement. One study indicated that DigiVis measurements are very reliable;<sup>25</sup> while another indicated good agreement between repeated iSight Professional and Peek Acuity

measurements, albeit with few statistics provided.<sup>22</sup> Again, pooling of iSight Professional and Peek Acuity data may have affected the result.<sup>22</sup>

All three tests with positive validation data had no requirement for real-time administration by a trained clinician. Therefore, all three may be used to improve the capability of telehealth services and eye assessment by non-specialists such as general practitioners and emergency department clinicians. However, as some patients in the DigiVis trial conducted the remote test in clinical settings, it is difficult to conclude with certainty that deployment for home-based assessment is justified.<sup>25</sup> All three tests relied on digital devices, accessible by most of the world's population.<sup>42</sup> As uptake of smartphone-based vision tests correlates negatively with older age and worse vision, healthcare providers should be mindful of patients' capacity to access and complete remote VA assessment to ensure their care and outcomes are not adversely affected.<sup>37</sup>

This review was limited by three factors: (1) Inconsistent and incomplete statistical analysis made establishing the accuracy and reliability of trialled VA tests challenging. *De novo* analysis and interpolation were conducted where amenable data were provided, and conclusions were restricted to what was indicated by available data. Deduction of the direction of bias was often based on limited prose descriptions—this is a potential source of error but would not affect conclusions significantly as bias was always close to 0. (2) Descriptions of the setting of the remote index test was often unclear, making the full-text screening process more difficult. Included studies all mentioned a test undertaken outside the eye clinic and did not state that all tests were conducted in clinical or ideal settings. (3) Most studies did not use Bailey-Lovie or ETDRS charts which are accepted as more

accurate and precise for clinical research. While this may inflate variability in the reference test and consequently inflate calculated accuracy of the remote index tests, use of Snellen chart may not be a specific weakness as it remains widespread in clinics around the world.<sup>43,44</sup>

Although promising technology has been developed to remotely assess VA, very few studies have demonstrated that patient-led assessment outside the eye clinic is feasible. DigiVis, iSight Professional, and Peek Acuity all have validation data demonstrating equivalence with clinical assessment, with the former being best justified due to conflicting results regarding the latter two tests. Further pragmatic trials are required to demonstrate the accuracy and reliability of remote VA assessment to justify deployment at scale—ongoing preregistered trials may fill this significant gap in the literature base.<sup>45,46</sup> However, as these trials are organised by test manufacturers, owners, or patent-holders, external research teams may seek to run their own studies to ensure validation data are unbiased. Reporting must be comprehensive—particularly in descriptions of patient characteristics, index test setting, and statistical analysis. Validated self-administered VA tests have the potential to augment teleophthalmology services, pre-consultation triage, long-term monitoring, as well as non-specialist assessment and reporting of eye problems.<sup>3</sup>

## **Funding**

This study was not supported by any funding.

## **Conflicts of Interest**

AJT worked from July 2020-March 2021 as an unpaid research intern on clinical validation projects for a remote visual acuity test, DigiVis.

## References

1. Walsh L, Hong SC, Chalakkal RJ, Ogbuehi KC. A Systematic Review of Current Teleophthalmology Services in New Zealand Compared to the Four Comparable Countries of the United Kingdom, Australia, United States of America (USA) and Canada. *Clin Ophthalmol*. 2021;15:4015-4027. doi:10.2147/OPTH.S294428
2. Caffery LJ, Taylor M, Gole G, Smith AC. Models of care in tele-ophthalmology: A scoping review. *J Telemed Telecare*. 2019;25(2):106-122. doi:10.1177/1357633X17742182
3. Li JPO, Liu H, Ting DSJ, et al. Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective. *Progress in Retinal and Eye Research*. 2021;82:100900. doi:10.1016/j.preteyeres.2020.100900
4. Samanta A, Mauntana S, Barsi Z, Yarlagadda B, Nelson PC. Is your vision blurry? A systematic review of home-based visual acuity for telemedicine. *J Telemed Telecare*. Published online November 22, 2020:1357633X20970398. doi:10.1177/1357633X20970398
5. Claessens JLJ, Geuvers JR, Imhof SM, Wisse RPL. Digital Tools for the Self-Assessment of Visual Acuity: A Systematic Review. *Ophthalmol Ther*. Published online June 25, 2021:1-16. doi:10.1007/s40123-021-00360-3
6. Kawamoto K, Stanojic N, Li JPO, Thomas PBM. Visual Acuity Apps for Rapid Integration in Teleconsultation Services in all Resource Settings: A Review. *The Asia-Pacific Journal of Ophthalmology*. 2021;10(4):350-354. doi:10.1097/APO.0000000000000384
7. Yeung WK, Dawes P, Pye A, et al. eHealth tools for the self-testing of visual acuity: a scoping review. *npj Digital Medicine*. 2019;2(1):1-7. doi:10.1038/s41746-019-0154-5
8. Gunasekeran DV, Tham YC, Ting DSW, Tan GSW, Wong TY. Digital health during COVID-19: lessons from operationalising new models of care in ophthalmology. *The Lancet Digital Health*. 2021;3(2):e124-e134. doi:10.1016/S2589-7500(20)30287-9
9. Saleem SM, Pasquale LR, Sidoti PA, Tsai JC. Virtual Ophthalmology: Telemedicine in a COVID-19 Era. *Am J Ophthalmol*. 2020;216:237-242. doi:10.1016/j.ajo.2020.04.029
10. Arditi A, Cagenello R. On the statistical reliability of letter-chart visual acuity measurements. *Invest Ophthalmol Vis Sci*. 1993;34(1):120-129.
11. Ford I, Norrie J. Pragmatic Trials. *New England Journal of Medicine*. 2016;375(5):454-463. doi:10.1056/NEJMra1510059



12. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. *Systematic Reviews*. 2016;5(1):210. doi:10.1186/s13643-016-0384-4
13. Whiting PF. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. *Ann Intern Med*. 2011;155(8):529. doi:10.7326/0003-4819-155-8-201110180-00009
14. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Research Synthesis Methods*. 2020;n/a(n/a). doi:10.1002/jrsm.1411
15. Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. *Journal of Open Source Software*. 2019;4(43):1686. doi:10.21105/joss.01686
16. Dayim A. forestploter. Published online January 3, 2023. Accessed January 3, 2023. <https://github.com/adayim/forestploter>
17. Adyanthaya S, B \* A. Comparison of visual acuity measured by ETDRS based smart phone applications I sight pro and Peek acuity versus traditional Snellen's chart visual acuity in children 6-14 years in a tertiary care institute in India. *Indian Journal of Clinical and Experimental Ophthalmology*. 2022;7(4):634-637. doi:10.18231/j.ijceo.2021.127
18. Almagati R., Kran B.S. Implications of a Remote Study of Children With Cerebral Visual Impairment for Conducting Virtual Pediatric Eye Care Research: Virtual Assessment Is Possible for Children With CVI. *Front Human Neurosci*. 2021;15((Almagati, Kran) New England College of Optometry (NECO), Boston, MA, United States):733179. doi:10.3389/fnhum.2021.733179
19. Bellsmith KN, Gale MJ, Yang S, et al. Validation of Home Visual Acuity Tests for Telehealth in the COVID-19 Era. *JAMA Ophthalmology*. Published online March 31, 2022. doi:10.1001/jamaophthalmol.2022.0396
20. Chen E, Mills M, Gallagher T, et al. Remote patient monitoring of central retinal function with MACUSTAT R: A multi-modal macular function scan. *Digit Health*. 2022;8(101690863):20552076221132104. doi:10.1177/20552076221132105
21. Chen TA, Li J, Schallhorn JM, Sun CQ. Comparing a Home Vision Self-Assessment Test to Office-Based Snellen Visual Acuity. *OPHTH*. 2021;15:3205-3211. doi:10.2147/OPHTH.S309727
22. Painter S, Ramm L, Wadlow L, O'Connor M, Sond B. Parental Home Vision Testing of Children During Covid-19 Pandemic. *British and Irish Orthoptic Journal*. 2021;17(1):13-19. doi:10.22599/bioj.157
23. Pathipati AS, Wood EH, Lam CK, Sáles CS, Moshfeghi DM. Visual acuity measured with a smartphone app is more accurate than Snellen testing by

- emergency department providers. *Graefes Arch Clin Exp Ophthalmol*. 2016;254(6):1175-1180. doi:10.1007/s00417-016-3291-4
24. Siktberg J, Hamdan S, Liu Y, et al. Validation of a Standardized Home Visual Acuity Test for Teleophthalmology. *Ophthalmology Science*. 2021;1(1):100007. doi:10.1016/j.xops.2021.100007
25. Thirunavukarasu AJ, Mullinger D, Rufus-Toye RM, Farrell S, Allen LE. Clinical validation of a novel web-application for remote assessment of distance visual acuity. *Eye*. 2022;36(10):2057-2061. doi:10.1038/s41433-021-01760-2
26. Van Der Star L, Mulders-Al-Saady R., Phan A., et al. First Clinical Experience with Ophthalmic e-Device for Unaided Patient Self-Examination during COVID-19 Lockdown. *Cornea*. 2022;41(3):353-358. doi:10.1097/ICO.0000000000002945
27. Allen L, Thirunavukarasu AJ, Podgorski S, Mullinger D. Novel web application for self-assessment of distance visual acuity to support remote consultation: a real-world validation study in children. *BMJ Open Ophthalmology*. 2021;6(1):e000801. doi:10.1136/bmjophth-2021-000801
28. Faes L., Islam M., Bachmann L.M., Lienhard K.R., Schmid M.K., Sim D.A. False alarms and the positive predictive value of smartphone-based hyperacuity home monitoring for the progression of macular disease: a prospective cohort study. *Eye*. 2021;35(11):3035-3040. doi:10.1038/s41433-020-01356-2
29. Haanes GG, Kirkevold M, Hofoss D, Eilertsen G. Discrepancy between self-assessments and standardised tests of vision and hearing abilities in older people living at home: an ROC curve analysis. *J Clin Nurs*. 2015;24(23-24):3380-3388. doi:10.1111/jocn.12967
30. Kaiser P.K., Wang Y.-Z., He Y.-G., Weisberger A., Wolf S., Smith C.H. FEasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld deviCES: Results of a pilot study. *Retina*. 2013;33(9):1863-1870. doi:10.1097/IAE.0b013e3182899258
31. Wang Y.-Z., He Y.-G., Mitzel G., Zhang S., Bartlett M. Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. *Invest Ophthalmol Vis Sci*. 2013;54(8):5497-5504. doi:10.1167/iovs.13-12037
32. Rono HK, Bastawrous A, Macleod D, et al. Smartphone-based screening for visual impairment in Kenyan school children: a cluster randomised controlled trial. *The Lancet Global Health*. 2018;6(8):e924-e932. doi:10.1016/S2214-109X(18)30244-4
33. Han X, Scheetz J, Keel S, et al. Development and Validation of a Smartphone-Based Visual Acuity Test (Vision at Home). *Transl Vis Sci Technol*. 2019;8(4):27. doi:10.1167/tvst.8.4.27

34. Bastawrous A, Rono H, Livingstone IA, et al. The Development and Validation of a Smartphone Visual Acuity Test (Peek Acuity) for Clinical Practice and Community-Based Fieldwork. *JAMA Ophthalmol.* 2015;133(8):930-937. doi:10.1001/jamaophthalmol.2015.1468
35. Guigou S., Michel T., Merite P.-Y., Coupier L., Meyer F. Home vision monitoring in patients with maculopathy: Real-life study of the OdySight application. *J Fr Ophthalmol.* 2021;44(6):873-881. doi:10.1016/j.jfo.2020.09.034
36. Harada S., Nakashima Y., Uematsu M., et al. Effectiveness of a photoscreener in identifying undiagnosed unilateral amblyopia at vision screening of 3-year-old children in Japan. *Jpn J Ophthalmol.* 2022;66(2):193-198. doi:10.1007/s10384-021-00896-8
37. Korot E., Pontikos N., Drawnel F.M., et al. Enablers and Barriers to Deployment of Smartphone-Based Home Vision Monitoring in Clinical Practice Settings. *JAMA Ophthalmol.* 2022;140(2):153-160. doi:10.1001/jamaophthalmol.2021.5269
38. Zur D, Loewenstein A. Development in Smartphone Technologies and the Advancement of Home Vision Monitoring. *JAMA Ophthalmology.* 2022;140(2):161. doi:10.1001/jamaophthalmol.2021.5270
39. Rosser DA, Cousens SN, Murdoch IE, Fitzke FW, Laidlaw DAH. How sensitive to clinical change are ETDRS logMAR visual acuity measurements? *Investigative Ophthalmology and Visual Science.* 2003;44(8):3278-3281. doi:10.1167/iovs.02-1100
40. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. *Journal of Chiropractic Medicine.* 2016;15(2):155-163. doi:10.1016/j.jcm.2016.02.012
41. Siderov J, Tiu AL. Variability of measurements of visual acuity in a large eye clinic. *Acta Ophthalmol Scand.* 1999;77(6):673-676. doi:10.1034/j.1600-0420.1999.770613.x
42. Smartphone users in the World 2028. Statista. Accessed January 31, 2023. <https://www.statista.com/forecasts/1143723/smartphone-users-in-the-world>
43. Yu HJ, Kaiser PK, Zamora D, et al. Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. *Ophthalmol Retina.* 2021;5(3):224-233. doi:10.1016/j.oret.2020.04.011
44. Lovie-Kitchin JE. Is it time to confine Snellen charts to the annals of history? *Ophthalmic Physiol Opt.* 2015;35(6):631-636. doi:10.1111/opo.12252
45. Tilak Healthcare. *Post-Market Study for At-Home Evaluation of Near Visual Acuity With OdySight, a Smartphone Based Medical Application in Comparison*

*to a Standardized Method (TIL002)*. [clinicaltrials.gov](https://clinicaltrials.gov); 2022. Accessed January 29, 2023. <https://clinicaltrials.gov/ct2/show/NCT05510479>

46. Gobiquity Mobile Health. *Comparison of Visual Acuity Performed in Office Versus In Residence*. [clinicaltrials.gov](https://clinicaltrials.gov); 2022. Accessed January 29, 2023. <https://clinicaltrials.gov/ct2/show/NCT05250986>

## Legends

**Figure 1. PRISMA flowchart.** Illustrating the literature search, screening process, and articles included in this review. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta Analyses; MEDLINE = Medical Literature Analysis and Retrieval System Online.

**Figure 2. Risk of bias and inapplicability appraisals for each included study.**

Appraised with the QUADAS-2 framework. QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies 2; RoB = risk of bias; CrA = concerns regarding applicability.

**Figure 3. Forest plot summarising Bland-Altman analyses of accuracy.** LLOA = lower 95% limit of agreement; ULOA = upper 95% limit of agreement; PDF = portable document format; ETDRS = Early Treatment of Diabetic Retinopathy Study; logMAR = logarithm of the minimum angle of resolution.

**Table 1. Characteristics of each of the included studies.** BCVA = best corrected visual acuity; VA = visual acuity; logMAR = logarithm of the minimum angle of resolution; PDF = portable document format; ETDRS = Early Treatment of Diabetic Retinopathy Study.

**Table 2. Accuracy data.** Comparing remote index tests to clinical reference tests. CI = confidence interval; LLOA = lower 95% limit of agreement; ULOA = upper 95%

limit of agreement; ICC = intraclass correlation coefficient; PDF = portable document format; ETDRS = Early Treatment of Diabetic Retinopathy Study.

**Table 3. Test-retest agreement.** Assessing the reliability of remote tests. CI = confidence interval; LLOA = lower 95% limit of agreement; ULOA = upper 95% limit of agreement; CoR = coefficient of repeatability; ICC = intraclass correlation coefficient.

**S1 Figure. Summarised risk of bias and inapplicability.** Appraised with the QUADAS-2 framework. QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies 2; RoB = risk of bias; CrA = concerns regarding applicability.

## Search, screening, and inclusion process

Identification

Records identified (N = 1227):  
MEDLINE (n = 211)  
Embase (n = 444)  
Scopus (n = 452)  
Cochrane (n = 78)  
Other sources<sup>4-7</sup> (n = 42)

Duplicates removed (n = 673):  
Automatic (n = 671)  
Manual (n = 2)

Screening

Records screened (n = 554)

Records excluded (n = 381)

Reports sought for retrieval  
(n = 173)

Reports not retrieved (n = 0)

Reports assessed for eligibility  
(n = 173)

Reports excluded (n = 163):  
Not in the English language (n = 5)  
Not a primary research article  
(n = 57)  
No visual acuity test undertaken  
outside clinic (n = 61)  
Remote test requires clinician  
administration (n = 31)  
No comparison of visual acuity  
measurements (n = 9)

Inclusion

Studies included in review<sup>17-26</sup>  
(n = 10)

Figure 1

# Risk of bias domains

	B1	B2	B3	B4	B5	A1	A2	A3	A4
17									
18									
19									
20									
21									
22									
23									
24									
25									
26									

medRxiv preprint doi: <https://doi.org/10.1101/2023.02.03.23285417>; this version posted February 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

B1: RoB in patient selection  
 B2: RoB in index test  
 B3: RoB in reference standard  
 B4: RoB in flow and timing  
**B5: Overall RoB**  
 A1: CrA in patient selection  
 A2: CrA in index test  
 A3: CrA in reference standard  
**A4: Overall CrA**

Appraisal:  
 Low  
 Some concerns  
 High

Figure 2




Figure 3